chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left arm became sore  around 8pm on 4/5/21. On the morning of 4/6/21, left arm was sore and I had some body aches and chills.  By 12:30 pm on 4/7/21, left arm still a little sore but body aches and chills are gone
A few minutes after vaccines, pt's face became red and seemed flushed. He said he felt hot and dizzy. We called 911. After 2 minutes he was perfect, and rescue said he was fine. No treatment.
I tested positive for COVID-19 on 02/24/2023 I was traveling back home from a trip. During the flight I started sweating and having double vision. I also had numbness on my left and fingers. I completed a course of PAXLOVID which caused me to have a Lupus flare up and hypertension of 150/100. Physician said that it was most likely a transsystemic episode during my flight. I continue to have numbness in my hand especially my fingers.
Fever, chills, sweating, lethargic, sore all over, throwing up, diarrhea, nauseous, headache, chest pains, dizziness.
c/o severe abd cramping/bloating associated w/trying to eat-minimal PO intake sx x 5dasy started 3 days p/vax;MD ordered BRAT diet;
Severe menstrual cycles. Heavy flow, severe pain, fatigue, and nausia; Severe menstrual cycles. Heavy flow, severe pain, fatigue, and nausia; Severe menstrual cycles. Heavy flow, severe pain, fatigue, and nausia; Severe menstrual cycles. Heavy flow, severe pain, fatigue, and nausia; Severe menstrual cycles. Heavy flow, severe pain, fatigue, and nausia; Extreme dehydration everyday; Loss of appetite; This is a spontaneous report from a contactable consumer (patient).   A 27-year-old not pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number EL9266) on 14Apr2020 (age at vaccination 27 year old) and second dose on 28Apr2021 (Lot number EL9266), both via an unspecified route of administration at single dose for COVID-19 immunization. Medical history was unknown. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No other medications received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 18May2021, patient experienced severe menstrual cycles, heavy flow, severe pain, fatigue, nausea, extreme dehydration every day, loss of appetite.  No treatment received. Outcome of events was not recovered.     Follow-up attempts are completed. No further information is expected.
pt stated swelling and redness. pain around the neck. no itching. md on call gave doxycycline on 12/20 thinking it was an infection.  pcp on 12/23 diagnosed a case of shingles
I had hives all over me in random spots that would come and go. Anytime something touched it, it got worse. I also had terrible chest pain. I ended up in the ER at the Hospital on November 18th. I wasn't diagnosed with anything, but I was told to follow up with a gastroenterologist and a dermatologist. I still have hives, but when I take Zyrtec it helps with it. I also have been taking Pepcid. I also have been having vaginal bleeding since I had received the booster.
Vaccine Saturday 12:30pm. Side effects: muscle ache, stomach ache, headache, nausea, fever, shivers. Began about 3am Sunday morning; Sunday, day after vaccine was height of side effects; 99.9 fever after Tylenol; fever did not return to normal until day 3 (Tuesday).
Patient received a vaccine that was stored beyond the 30 days recommended in the refrigerated state. This event was reported to the manufacturer. The manufacturer tested the lot number in question. Data revealed that the vaccine administered did not maintain activity necessary to protect against the SARS-CoV-2 (COVID-19) virus at time of administration. Healthcare facility  consulted with the regulatory authority and recommended repeating this dose in question. Patient was sent a letter to inform them of the need to repeat the dose in question. Healthcare facility is working with the regulatory authority on a compliance improvement plan and has been reinstated vaccination privileges.
EMS called to pt's house due to confusion and generalized weakness; O2 saturation 62% on RA; placed on NRB; cold-like sx x8days; increase in O2 needs; placed on BiPAP; positive for COVID; AHRF; Pneumonia due to COVID; given Decadron, ABX, Remdesivir, Baricitinib; DNR/DNI; pt took BiPAP off several times; eventually was transitioned to comfort care; pt passed away in the hospital
Approximately 20 hours after vaccination patient felt faint, lost all color and fainted. She was in and out of responsiveness. Patient was transported to the ER. Patient was treated with fluids and discharged after observation. According to patient's mom the EKG and lab work were unremarkable. Patient has fully recovered.
Approximately 2 hours following vaccination, pt began to feel weak and tired and blood glucose began to trend down. Approximately 4 hours after, began to develop severe hypoglycemia that was not responsive to treatment at home.  This resulted in  24 hour hospital admission and dextrose administration. Eventually, BG returned to normal and pt was discharged on home insulin pump.
Initial report received from a patient on 01 February 2007. A 27 year old, female patient (with an allergy to erythromycin) experienced arm soreness and mild lethargy, 1 day after she received a 0.5 mL IM injection of Adacel (lot number unknown) in the left deltoid on 24 January 2007. She was not treated with medicines. She did not have any illness at the time of vaccination. She received her last Td 10 year ago. The patient recovered from the adverse events in 3 days. The patient had a positive home pregnancy test on 29 January 2007. Her last menstrual period was "16 December 2006" or "30 December 2006" and her expected date of delivery is "25 September 2007" or "05 October 2007" (dependent on OB/GYN exam). The pregnancy has not yet been confirmed by the patient's OB/GYN and no prenatal testing has been conducted as of yet. She has had 3 previous pregnancies, 1 of which was a full term delivery and 2 of which were pre-term births. All had normal/viable pregnancy outcomes.
Subsequent to receiving one dose of varicella virus vaccine live the pt experienced six red spots with pustules. Two were crusted over. There were four new ones at the time of this report. Follow up indicated there was no increase in the number of lesions. The lesions crusted over within three days and the child recovered fully.
first dose / 21Aug2020 / attended / clinic / 01Sep2020 / symptoms / 1 or 2 days before; This case was reported by a physician via call center representative and described the occurrence of shingles in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st August 2020, the patient received the 1st dose of Shingrix. In August 2020, 1 week after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported.  The reporter called to request information of how often did patients have a shingles outbreak after a first dose of Shingrix administration. On 1st Sep 2020 patient attended physician clinic and mentioned that symptoms could have been there 1 or 2 days before the consult.  Patient had the vaccine administered at another location. The reporter consented to follow up.
elevated alkaline phosphatase; elevated bilirubin; This case was reported by a consumer via call center representative and described the occurrence of alkaline phosphatase increased in a 60-year-old female patient who received Herpes zoster (Shingrix) (batch number BF4J5, expiry date 5th July 2021) for prophylaxis.   Concurrent medical conditions included immunoglobulin g low.   On 31st July 2019, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 1st August 2019, 1 days after receiving Shingrix, the patient experienced alkaline phosphatase increased and bilirubin increased. On an unknown date, the outcome of the alkaline phosphatase increased and bilirubin increased were unknown.   It was unknown if the reporter considered the alkaline phosphatase increased and bilirubin increased to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient herself. 3 months before reporting date, patient's blood levels were normal. After receiving the Shingrix, patient's standard yearly blood test showed alkaline phosphatase and bilirubin were high. For 21st August 2019, the patient had another blood test scheduled. The reporter did not consent to follow-up.
Administered an adult with pediatric dose; Administered an adult with pediatric dose; This case was reported by a nurse via call center representative and described the occurrence of accidental underdose in a 39-year-old female patient who received HBV (Engerix B pediatric) (batch number MY3RA, expiry date 21st September 2022) for prophylaxis.   On 1st March 2022, the patient received the 2nd dose of Engerix B pediatric. On 1st March 2022, unknown after receiving Engerix B pediatric, the patient experienced accidental underdose and adult use of a child product. On an unknown date, the outcome of the accidental underdose and adult use of a child product were unknown.  Additional details reported were as follows: The reporter accidentally administered an adult with a pediatric dose of Engerix-B for their 2nd dose, which led to accidental underdose and adult use of a child product. The reporter consented to follow up.
NO medical intervention required. For reporting purposes ONLY. Within about five minutes, throat swelled but not to the point of concern.  Don't remember reactions to previous vaccines but not surprised considering allergies. Left side of face felt strange but didn't look any different when a selfie was taken. Sometime during the afternoon/evening, experienced a headache of short duration. Approximately six hours after shot, experienced chills and low grade fever. Simply went to sleep. Better the following morning, though very tired.  Probably unelated rough itchy patch on RIGHT arm the day following vaccine. Went away with no treatment.
This spontaneous report as received from a health professional refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 26-OCT-2015, the patient was vaccinated with improperly stored (exposed to the following temperatures an cumulative time frames colder than 36 F: In September of 2015, the coldest temperature was 34 F for 346.7 hours (over 14 days); In October of 2015, the coldest temperature was 34 F for 492.6 hours for a total of 839.3 hours (35 days); In November of 2015, the coldest temperature was 34 F for 192 hours, for a total of 1,031.3 hours (43 days)) VAQTA injection, 0.5 ml (lot # L028666, exp. date: 04-NOV-2016) (route and strength unspecified). No concomitant medications were reported. No adverse effects have been reported. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports received from the same reporter. Additional information has been requested.
Patient said within an hour after her pneumovax vaccination, her arm was swollen, red, and painful. It has gotten better each day, but her whole arm was red and swollen.
Left sided parotid swelling, 9 hrs after injection.  Pain in cheek and ear.  No fever, gave motrin.  Saw next day in office.
Patient lost sense of smell 5 days after her booster dose of the COVID vaccine.  She states symptoms completely resolved about 3 weeks ago.
pt recv vax 9FEB95 & 19FEB95 pt to MD w/rectal bleeding, ill-defined abd discomfort, bilat leg pain & tightness;devel diffuse swelling of lower legs & bands;pt lost 10 pounds;devel edema of hand & feet gain 7 lb;wrist synovitis;
dry cough; sore throat; Caller is less than 50 years old; This case was reported by a consumer via call center representative and described the occurrence of dry cough in a 41-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included ulcerative colitis. Concomitant products included prednisone.   On 19th March 2021, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 19th March 2021, less than a day after receiving Shingrix, the patient experienced dry cough, sore throat and inappropriate age at vaccine administration. On an unknown date, the outcome of the dry cough and sore throat were recovering/resolving and the outcome of the inappropriate age at vaccine administration was unknown.   It was unknown if the reporter considered the dry cough and sore throat to be related to Shingrix.  Additional case details were reported as follows: The patient reported case for herself. The patient received immunosuppressive medication prednisone as concomitant medication. The patient received vaccine at the age of 41 years which led to inappropriate age at vaccine administration. The patient reported dry cough and sore throat within 12 hours of receiving first dose of Shingrix. The reporter consented to follow up.
Pt recvd DTP/HIB/OPV 17DEC91 & on 25DEC91 pt ha a febrile sz which lasted 1 min t101.6;
COVID+ 5/10, developed sore throat 5/9. Other family members also symptomatic including minor children and mother in law (husband vaccinated, symptomatic since 5/2), unknown COVID test results at this time for rest of household.
DATE: 02/07/2021 This nurse received a call from CLA/CMT at 0823 stating client is grunting and wheezing while breathing with a SpO2 of 86.  This nurse instructed CLA/CMT to call 911 and get complete vitals.  CLA/CMT called back with CVS: 149/106, 130, 97.7, 86.  Residental support director was notified at 0828,  Executive Director was notified @ 0843.  Parents were notified via telephone call by this nurse @ 0922. 1109: Residential Support Director states via text ?.  (name) called. (name) will need to wait for ambulance.  Labs and lungs are good.  Probably side effect from vaccine.?  This nurse updated the parents and the ED. 1205: Ordered cvs every 4 hours and through the night with cvs reported to RN x 24 hours. 1230: returned from the ED with order for albuterol MDI 2 puffs every 4 hours as needed for coughing and wheezing. This nurse spoke to (name) at PCI.  Requested chamber at cash price.  Staff aware to call nurse when delivered.
Symptoms and timeline apply for both shots 1 and 2 EXCEPT FOR acid reflux only following shot 2.  Day of shot: moderate lethargy starting four hours after administration, lasting until sleep. Increasing soreness at site of shot starting one hour after. Shot day +1: woke with moderate soreness in joints, heavy muscle soreness, the latter of which lasted the whole day.  Overall feeling of fatigue, and the sensation of riding on an endlessly looping rollercoaster lasted for half the day. In the second half of the day, congested sinuses and light coughing/sneezing began, along with light acid reflux. Shot day +2: Muscle soreness mostly gone, small amount of nausea remaining in the morning. Light fatigue. Frequent coughing in the morning, and heavy acid reflux throughout the day. Shot day +3: Symptoms minimal
I got increasingly worse pressure in my chest. It became painful down the back of my arms and in my jaw. I then made me appointment to see a cardiologist. On 5/28/2021, I had a procedure and a stint was put in my artery. I was diagnosed with arteriosklerosis.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Jul2022 as dose 4 (booster), single (Lot number: FM0173) at the age of 50 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 03May2021 as dose 1, single (Lot number: EW0176), in left arm, on 24May2021 as dose 2, single (Lot number: EW0187), in left arm and on 17Dec2021 as dose 3 (booster), single (Lot number: FE3594), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: latex" (unspecified if ongoing); "Known allergies: Wellbutrin, Benadryl" (unspecified if ongoing). Concomitant medication(s) included: TRETINOIN, start date: Apr2021; ALLERTEC [CETIRIZINE], start date: Jan2021; NEXIUM [ESOMEPRAZOLE MAGNESIUM], start date: May2022. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: Body mass index: 29.5. Therapeutic measures were taken as a result of vaccination failure, covid-19. Treatment included Paxlovid.
Pt seen in parking lot next day p/immun by RN told had temp 104 r; Was instructed to take Hosp for eval; Told was not rxn; Taken to ER same night 28FEB91 w/t105;
vaccine given 16 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 16 days post expiry) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 16 days post expiry). On 22-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 16 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.   This case was linked to MOD-2021-395985 (Patient Link).
Chilling, shivering, fever, headache, muscle ache for 12 hours, followed by 12 hours of extreme weakness.  A follow up report received 10/28/2003 adds: No Rx, no Dx.
I have a couple of autoimmune issues and because of this I recieved the booster shot. Almost 2 weeks after my lichen planus flared up worse than ever and now it has spread to place I've never experienced. With my first two Pfizer shot I did not experience this.  I am seeing a dermatologist and explained my current issue.  We have increased my steroids so what effect does that have on the vaccine?  I got the booster on September 3rd and started noticing the first flare up around September 13th. Still dealing with lichen planus and the increase of prednisone is not helping.
Syncope upon administration, helped pt to floor, BP 78/58, put in Trendelenburg position, 1220 p BP 100/62 went home at 139p.
DIZZINESS; CIRCULATION PROBLEMS WITH FEET, HANDS AND KNEES; INCREASING NEED FOR PHYSIOTHERAPY; JOINT PAINS; FINGERS TINGLING; FAINTED ON THE INJECTION DAY; This spontaneous report received from a patient concerned a 62 year old adult female. The patient's height, and weight were not reported. The patient's concurrent conditions included: lupus. The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of administration not reported, batch number: 042A21A expiry: unknown) dose was not reported, 01 total administered in left arm on 02-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 02-APR-2021, the patient fainted on the injection day. On an unspecified date, the patient had dizziness, circulation problems with feet, hands and knees, increasing need for physiotherapy, joint pains, and fingers tingling. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the dizziness, circulation problems with feet, hands and knees, fingers tingling, joint pains, increasing need for physiotherapy and fainted on the injection day was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20211116539-COVID-19 VACCINE AD26.COV2.S-fainted on the injection day. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Rigors for 2 hours. Needed to take an NSAID to stop them.
Pt received FLUVIRIN 10/2/09. Pt presented 10/5/09 with a rash on his trunk region. Pt had taken a BENADRYL and was advised to take more BENADRYL and an oatmeal bath. Pt stated he was not having any problems breathing. Pt did not have swelling of the eyes, throat.
By 6 PM had 2 red raised dots on neck area, by following AM 2 more spots flank and shoulder, day 3 entire buttocks broken out.  Saw Dr. who documented as exanthem viral. Started high dose vitamin C treatment and the spots resolved.
Initial report received on 24 October 2008 from a consumer. A female patient (demographics not provided) had received a dose of Influenza vaccine on an unspecified date. The trade name, manufacturer name, route and site of administration of the flu vaccine was not provided. The patient reported that she thinks she might be developing Bell's Palsy after receiving the flu shot. It was not reported whether the patient had any concurrent illnesses, or past medical history at the time of the Influenza vaccination. The patient was subsequently evaluated by a physician; however the outcome of the physician evaluation was not provided. It was not reported whether any relevant diagnostic testings had been completed. The recovery status of the patient was not reported. Follow-up information received on 03 November 2008 from a physician. Per the reporter, the female patient had received vaccination with FLUZONE SV 2008-2009 (date of vaccination, lot number, route and site of administration were not provided) approximately one week prior to this report, which would make the vaccine administration date some time in October 2008. The patient was anxious about receiving the vaccination since she had never received a flu shot before. Approximately a day or two following the vaccination, the patient stated she did not feel well and believed she received Bell's Palsy from the vaccine. The facility where the patient was vaccinated is awaiting a complete diagnosis from the patient's family physician. The nurse at the facility where the patient had received the vaccination will stay in touch with the manufacturer and will ensure all proper VAERS forms and paperwork is completed. Documents held by sender: None.